On September 18, House Select Committee on China chairman John Moolenaar wrote to Trump urging him to close the "cloud services loophole" in chip export controls. Less than a week before Xi Jinping's first state visit to the White House since 2015, the letter's real weight falls on a second ask: cur
Paramount Skydance's roughly $110 billion purchase of Warner Bros. Discovery cleared its last legal obstacle this week, and the list of what one company now controls is almost absurd to read in one sentence: CBS and CNN, HBO and MTV, SpongeBob and Bugs Bunny, Harry Potter and Transformers. The feder
A tweet promoting a podcast with oncologist Azra Raza asks whether medicine should chase cancer's first cell instead of its last. The technology closest to doing that, GRAIL's Galleri blood test, had its first-ever FDA advisory panel hearing today. What it actually finds, what a 142,942-person trial
A WEHI-led study of roughly 900 gut biopsies from 80 people, published in Science, finds that intestinal cells in inflammatory bowel disease patients can stay primed for an inflammatory kind of cell death even during symptom-free remission — and the stronger that signal, the higher the relapse risk
A biotech company is about to put the first GPX4-modulating "senolytic" into a human trial for male pattern hair loss, after ex vivo human follicle data that matched or beat finasteride. It's a genuinely new mechanism after nearly thirty years of the same two drugs — but the data so far is six days
AIR Security disclosed "Plugin4Shell" on September 17, 2026 — a zero-click flaw in Claude Code, OpenAI Codex, GitHub Copilot and Gemini CLI that let a hijacked git branch silently swap in different code than the one a plugin manifest had pinned by commit hash. OpenAI's own four-line patch note descr
Novo Nordisk says its experimental drug CagriSema beat Eli Lilly's tirzepatide on weight loss in a head-to-head diabetes trial. It did — against a 5mg dose, not tirzepatide's strongest one. A second trial released the same day, against the 15mg dose, went the other way.
On September 22, 2026, Anthropic shipped Claude Opus 5.5 — its first new model since CEO Dario Amodei published an essay ten days earlier arguing the whole industry should deliberately slow down. It's 40 percent cheaper than Opus 5, runs about 30 percent faster, performs close to the pricier Fable 5
A UK Biobank study of 11,071 adults found that people with bedroom light above roughly 3 lux at night — dimmer than almost any lamp, but bright enough for closed eyes to register — developed a thicker, stiffer-pumping heart and higher rates of heart failure, stroke and atrial fibrillation years late